Moderna has begun testing an omicron-specific COVID-19 booster in wholesome adults.
The corporate introduced Wednesday that the primary participant had acquired a dose. Earlier this week, competitor Pfizer started an identical examine of its personal reformulated pictures.
For extra coronavirus information, go to our devoted web page.
It’s not clear whether or not international well being authorities will order a change to the vaccine recipe within the wake of the massively contagious omicron variant. The unique vaccines nonetheless supply good safety towards demise and extreme sickness. Research within the US and elsewhere present a booster dose strengthens that safety and improves the possibilities of avoiding even a milder an infection.
Moderna pointed to a small examine revealed within the New England Journal of Medication on Wednesday that confirmed antibodies capable of goal omicron persevered for six months after a booster dose, though the degrees had been dropping.
Moderna’s new examine will enroll about 600 individuals who have already got acquired both two doses of the corporate’s unique pictures or two plus a booster dose. All of the volunteers will obtain a dose of the experimental omicron-matched model.
For the most recent headlines, comply with our Google Information channel on-line or by way of the app.
Moderna CEO says engaged on omicron-specific vaccine: Interview
Pfizer-BioNTech start omicron COVID-19 vaccine trial: Assertion
Valneva COVID-19 vaccine neutralizes omicron in early lab exams